Cost-effectiveness of psychotherapies and pharmacotherapies for mental disorders

Short-term psychodynamic psychotherapies for common mental disorders.

BACKGROUND Since the mid-1970s, short-term psychodynamic psychotherapies (STPP) for a broad range of psychological and somatic disorders have been developed and studied. Early published meta-analyses of STPP, using different methods and samples, have yielded conflicting results, although some meta-analyses have consistently supported an empirical basis for STPP. This is an update of a review th...

New psychotherapies for mood and anxiety disorders.

OBJECTIVE To discuss psychotherapies for depression and anxiety that have emerged in recent years and to evaluate their current level of empirical support. METHOD An electronic and a manual literature search of psychotherapies for mood and anxiety disorders were conducted. RESULTS Five new therapies for mood disorders and 3 interventions for posttraumatic stress disorder with co-occurring s...

Cost-effectiveness and mental health

Costs and benefits of improving access to psychotherapies for common mental disorders.

BACKGROUND Structured psychotherapies are treatments used in common mental health disorders (CMHDs) that are recommended by international good practice guidelines. Their efficacy and positive impact on health--and thereby on the reduction of related costs for health insurance schemes and society--have been widely demonstrated. However in France, despite the considerable financial burden of CMHD...

Neurogenetic Disorders of Down Syndrome and Potential Pharmacotherapies for Mental Retardation

Background: Trisomy of human chromosome 21 is the most frequent genetic cause of mental retardation or intellectual disability and others phenotypes, including developmental defects, dysmorphic features and cognitive impairments collectively known as Down syndrome. Mainly a consequence of developmental and functional brain alterations, the mental retardation is the most invariable and invalidat...